About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

NCT01057810·134 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Bristol-Myers Squibb

Age

18–any

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Metastatic prostate cancer
Asymptomatic or minimally symptomatic
Progression during hormonal therapy
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

You may not be if

Liver, lung or brain metastases
Prior immunotherapy or chemotherapy for metastatic prostate cancer
Autoimmune disease
HIV, Hepatitis B, or Hepatitis C infection

The record

StatusCompleted

PhasePhase 3

Taking part837

StartedJul 2010

UpdatedAug 18, 2016

Conditions

Prostate Cancer

Where134

Alaska Clinical Research Center, Llc
Anchorage, Alaska, United States
Pinnacle Oncology Hematology
Scottsdale, Arizona, United States
Arizona Cancer Center
Tucson, Arizona, United States

Clareo Health | Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer